B BRAUN L8061 SODIUM CHLORIDE INJECTIONS USP Sodium Chloride Injections, 5%, 500mL, EXCEL® Container (Hypertonic), 24/cs Max weekly quantity allowed: 10

B BRAUN L8061 SODIUM CHLORIDE INJECTIONS USP Sodium Chloride Injections, 5%, 500mL, EXCEL® Container (Hypertonic), 24/cs Max weekly quantity allowed: 10

• Model: L8061
• Volume: 500 mL
• Case of 24

EXCEL & PAB, the only PVC-free, DEHP-free containers with a full range of basic IV solutions. EXCEL & PAB eliminate the risk of plasticizer toxicity, reduces the risk of sub-therapeutic dosing and facilitate inspection of admixtures.

The B. Braun L8061 5% Sodium Chloride Injection USP (500 mL) provides a hypertonic sodium chloride solution delivered in a modern EXCEL® IV bag format. With a 5% concentration, this solution offers a significantly elevated sodium and chloride load compared to isotonic fluids, making it suitable for clinical scenarios where there is a severe sodium or chloride deficit or when rapid rapid replenishment is indicated. The high osmolarity (~1,710 mOsmol/L) and electrolyte concentration (~856 mEq/L sodium and chloride) mean that careful patient monitoring is essential; infusion must be administered slowly under observation to avoid risks such as fluid overload or pulmonary edema.

From a materials and operational viewpoint, this product is engineered with safety and workflow considerations in mind. The EXCEL® bag format ensures that the container is free from PVC, DEHP, and natural rubber latex—important factors in reducing patient exposure to plasticizers and allergens. The specific gravity of about 1.034 indicates the denser nature of this hypertonic solution relative to standard isotonic fluids. The 24‑units per case packaging supports institutional stocking, and the flexible bag format simplifies handling, set‑up, and disposal.

Clinically, this hypertonic sodium chloride bag fits into specialized but critical use‑cases: for example, in patients experiencing severe salt depletion (such as in massive sweating, vomiting/diarrhea, or post‑operative states), in certain neurologic or renal conditions requiring controlled sodium elevation, or in settings where chloride loss exceeds sodium loss. Because of the concentrated nature of the solution, it should not be used as first‑line routine hydration but rather in targeted therapy according to institutional protocols. Procurement teams should ensure that staff understand its proper use, monitor for potential over‑infusion risk, and confirm case supply meets the institution’s specialized needs while controlling ordering carefully.